trial · primary record
Fostamatinib
Sickle Cell Disorders
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 35 |
| Primary completion | 2027-05-14 |
| Primary endpoint | Safety and tolerability of fostamatinib |
| Registry ID | NCT05904093 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:04.989Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05904093
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- fostamatinib · compound